Track topics on Twitter Track topics that are important to you
Shares of AMAG Pharmaceuticals Inc. (AMAG) are nearly 43% down from its 52-week high of $25.20 that was recorded on March 8, 2017. With two of the Company's drugs awaiting FDA decision for label expansion, there could be some sharp movement in the level of its stock price in February, depending upon the outcomes.
Original Article: Double Blessing Or Double Whammy - What Awaits AMAG?NEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...